Meeting
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
A phase II trial of consolidation nivolumab or nivolumab plus ipilimumab following concurrent chemoradiation in unresectable stage III NSCLC: BTCRC LUN16-081.
Authors
Greg Andrew Durm
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
Greg Andrew Durm, Susan M. Perkins, Nasser H. Hanna
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B
Track
Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Breast and Gynecologic Cancers,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Oncolytic Viruses
Sub Track
Immune Checkpoints and Stimulatory Receptors
Clinical Trial Registration Number
NCT03285321
Citation
J Clin Oncol 36, 2018 (suppl 5S; abstr TPS179)
DOI
10.1200/JCO.2018.36.5_suppl.TPS179
Abstract #
TPS179
Poster Bd #
N3
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Analysis of circulating tumor DNA in the phase 2 BTCRC LUN 16-081 trial of consolidation nivolumab with or without ipilimumab after chemoradiation in stage III non–small cell lung cancer.
First Author: Soyeong Jun
Poster
2023 ASCO Annual Meeting
Association of immune-related adverse events and efficacy outcomes in phase II trial of consolidation nivolumab plus ipilimumab or nivolumab alone after chemoradiation in patients with unresectable stage III non–small-cell lung cancer (NSCLC).
First Author: Cynthia Wei
Poster
2022 ASCO Annual Meeting
Consolidation nivolumab plus ipilimumab or nivolumab alone following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: BTCRC LUN 16-081.
First Author: Greg Andrew Durm
Poster
2020 ASCO Virtual Scientific Program
Consolidation nivolumab/ipilimumab versus nivolumab following concurrent chemoradiation in patients with unresectable stage III NSCLC: A planned interim safety analysis from the BTCRC LUN 16-081 trial.
First Author: Melissa Yan